Moderna Taiwan Co (莫德納台灣) has begun recruiting participants for its flu vaccine trial and expects to disclose the results in March next year, the company said yesterday.
Taiwan is the only Asian country where US-based Moderna Inc is conducting clinical trials for its flu vaccine.
Moderna Taiwan is collaborating with eight hospitals or medical centers for the enrollment, but it has not set a target number of participants as the clinical trial uses competitive enrollment, which means when a target number of subjects have been meet, all enrollment ceases, general manager Joyce Lee (李宜真) told a media briefing in Taipei.
Photo: EPA-EFE
“We should be able to have some readout of the human test in March next year. This [rate of human test] is comparatively high, as speed is in the DNA of Moderna, which utilizes messenger RNA technology,” Lee said.
Taiwan is also the first Asian market to introduce Moderna’s BA.4/BA.5-adapted bivalent vaccine for COVID-19, she added.
Moderna Taiwan aims to introduce the latest mRNA technology to Taiwan and would try to participate in as many multination clinical trials by its parent company as possible, Lee said.
Launched in September, Moderna Taiwan is recruiting more staff for business and marketing, with an eye to increasing the number of employees to 10 next year, Lee said.
Asked if Moderna would continue supplying Taiwan with its latest COVID-19 vaccine, Patrick Bergstedt, Moderna’s senior vice president and head of emerging markets, said that the company is in talks with all stakeholders, including the Ministry of Health and Welfare.
“We need to remember that we are not dealing with the same coronavirus that caused the pandemic in 2020 — the virus has evolved,” Bergstedt said.
The world cannot assume that COVID-19 will be the last global pandemic, so Moderna is researching and developing vaccines for 15 viruses that are emerging or have been ignored, but might cause the greatest health threat to human beings by 2025, Bergstedt said.
Overall, Moderna would focus on respiratory viruses, he said.
The company is also researching non-invasive vaccines, which might be administered in the form of a nasal spray or patch, he added.
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday said that its investment plan in Arizona is going according to schedule, following a local media report claiming that the company is planning to break ground on its third wafer fab in the US in June. In a statement, TSMC said it does not comment on market speculation, but that its investments in Arizona are proceeding well. TSMC is investing more than US$65 billion in Arizona to build three advanced wafer fabs. The first one has started production using the 4-nanometer (nm) process, while the second one would start mass production using the
A TAIWAN DEAL: TSMC is in early talks to fully operate Intel’s US semiconductor factories in a deal first raised by Trump officials, but Intel’s interest is uncertain Broadcom Inc has had informal talks with its advisers about making a bid for Intel Corp’s chip-design and marketing business, the Wall Street Journal reported, citing people familiar with the matter. Nothing has been submitted to Intel and Broadcom could decide not to pursue a deal, according to the Journal. Bloomberg News earlier reported that Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is in early talks for a controlling stake in Intel’s factories at the request of officials at US President Donald Trump’s administration, as the president looks to boost US manufacturing and maintain the country’s leadership in critical technologies. Trump officials raised the
‘SILVER LINING’: Although the news caused TSMC to fall on the local market, an analyst said that as tariffs are not set to go into effect until April, there is still time for negotiations US President Donald Trump on Tuesday said that he would likely impose tariffs on semiconductor, automobile and pharmaceutical imports of about 25 percent, with an announcement coming as soon as April 2 in a move that would represent a dramatic widening of the US leader’s trade war. “I probably will tell you that on April 2, but it’ll be in the neighborhood of 25 percent,” Trump told reporters at his Mar-a-Lago club when asked about his plan for auto tariffs. Asked about similar levies on pharmaceutical drugs and semiconductors, the president said that “it’ll be 25 percent and higher, and it’ll
CHIP BOOM: Revenue for the semiconductor industry is set to reach US$1 trillion by 2032, opening up opportunities for the chip pacakging and testing company, it said ASE Technology Holding Co (日月光投控), the world’s largest provider of outsourced semiconductor assembly and test (OSAT) services, yesterday launched a new advanced manufacturing facility in Penang, Malaysia, aiming to meet growing demand for emerging technologies such as generative artificial intelligence (AI) applications. The US$300 million facility is a critical step in expanding ASE’s global footprint, offering an alternative for customers from the US, Europe, Japan, South Korea and China to assemble and test chips outside of Taiwan amid efforts to diversify supply chains. The plant, the company’s fifth in Malaysia, is part of a strategic expansion plan that would more than triple
RSS